ERBB2 and breast cancer: The humanized mouse monoclonal antibody Herceptin® (namely trastuzumab) targeting the extracellular domain (ECD) of HER2 is nowadays offered to breast cancer patients in advanced, adjuvant, and neoadjuvant settings in association with chemotherapy.